DK3085386T3 - Fremgangsmåde til hæmning af knogleresorption - Google Patents

Fremgangsmåde til hæmning af knogleresorption Download PDF

Info

Publication number
DK3085386T3
DK3085386T3 DK16162068.7T DK16162068T DK3085386T3 DK 3085386 T3 DK3085386 T3 DK 3085386T3 DK 16162068 T DK16162068 T DK 16162068T DK 3085386 T3 DK3085386 T3 DK 3085386T3
Authority
DK
Denmark
Prior art keywords
bone resorption
inhibiting bone
inhibiting
resorption
bone
Prior art date
Application number
DK16162068.7T
Other languages
English (en)
Inventor
Ian Desmond Padhi
Graham Richard Jang
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40371592&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3085386(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Inc filed Critical Amgen Inc
Application granted granted Critical
Publication of DK3085386T3 publication Critical patent/DK3085386T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/08—Antibacterial agents for leprosy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Child & Adolescent Psychology (AREA)
DK16162068.7T 2007-09-17 2008-09-17 Fremgangsmåde til hæmning af knogleresorption DK3085386T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US97302407P 2007-09-17 2007-09-17
EP12180292.0A EP2556841B9 (en) 2007-09-17 2008-09-17 Method for inhibiting bone resorption

Publications (1)

Publication Number Publication Date
DK3085386T3 true DK3085386T3 (da) 2020-09-28

Family

ID=40371592

Family Applications (4)

Application Number Title Priority Date Filing Date
DK16162068.7T DK3085386T3 (da) 2007-09-17 2008-09-17 Fremgangsmåde til hæmning af knogleresorption
DK12180292.0T DK2556841T3 (da) 2007-09-17 2008-09-17 Fremgangsmåde til hæmning af knogleresorption
DK08832690.5T DK2195026T3 (da) 2007-09-17 2008-09-17 Anti-sclerostin-antistoffer
DK20174310.1T DK3725329T3 (da) 2007-09-17 2008-09-17 Fremgangsmåde til hæmning af knogleresorption

Family Applications After (3)

Application Number Title Priority Date Filing Date
DK12180292.0T DK2556841T3 (da) 2007-09-17 2008-09-17 Fremgangsmåde til hæmning af knogleresorption
DK08832690.5T DK2195026T3 (da) 2007-09-17 2008-09-17 Anti-sclerostin-antistoffer
DK20174310.1T DK3725329T3 (da) 2007-09-17 2008-09-17 Fremgangsmåde til hæmning af knogleresorption

Country Status (21)

Country Link
US (7) US8017120B2 (da)
EP (5) EP2556841B9 (da)
JP (2) JP5643094B2 (da)
AR (2) AR068471A1 (da)
AU (1) AU2008302313C1 (da)
CA (2) CA2699905C (da)
CL (1) CL2008002775A1 (da)
CY (3) CY1114961T1 (da)
DK (4) DK3085386T3 (da)
ES (3) ES2815677T3 (da)
FI (1) FI3725329T3 (da)
HK (1) HK1182017A1 (da)
HR (3) HRP20140153T1 (da)
HU (2) HUE050653T2 (da)
LT (3) LT3085386T (da)
MX (1) MX2010002971A (da)
PL (4) PL3085386T3 (da)
PT (4) PT3085386T (da)
SI (4) SI3085386T1 (da)
TW (2) TWI612972B (da)
WO (1) WO2009039175A2 (da)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101469329B (zh) 1998-11-27 2012-10-24 达尔文发现有限公司 增加骨矿化的组合物和方法
EA015166B1 (ru) 2003-06-16 2011-06-30 Ю-Си-Би Мэньюфэкчуринг, Инк. Иммуногенные пептиды склеростина (sost), индуцирующие образование специфических антител
US7592429B2 (en) 2005-05-03 2009-09-22 Ucb Sa Sclerostin-binding antibody
US8003108B2 (en) 2005-05-03 2011-08-23 Amgen Inc. Sclerostin epitopes
US20100015665A1 (en) * 2006-11-10 2010-01-21 Ucb Pharma S.A. Antibodies and diagnostics
US20100036091A1 (en) * 2006-11-10 2010-02-11 Amgen Inc. Antibody-based diagnostics and therapeutics
EP3345607B1 (en) 2006-12-29 2022-10-26 Ossifi-Mab LLC Methods of altering bone growth by administration of sost or wise antagonist or agonist
CL2008002775A1 (es) 2007-09-17 2008-11-07 Amgen Inc Uso de un agente de unión a esclerostina para inhibir la resorción ósea.
AR068767A1 (es) 2007-10-12 2009-12-02 Novartis Ag Anticuerpos contra esclerostina, composiciones y metodos de uso de estos anticuerpos para tratar un trastorno patologico mediado por esclerostina
US20090142766A1 (en) * 2007-11-09 2009-06-04 Washington University In St. Louis Methods for measuring the metabolism of cns derived biomolecules in vivo
US20110044978A1 (en) * 2007-12-14 2011-02-24 Amgen Inc. Method for treating bone fracture
DK2708559T3 (da) 2008-04-11 2018-06-14 Chugai Pharmaceutical Co Ltd Antigenbindende molekyle, som er i stand til gentagne at binde to eller flere antigenmolekyler
BR112012028920B1 (pt) 2010-05-14 2021-03-23 Amgen Inc. Formulações líquidas estéreis de anticorpo de alta concentração e método para reduzir a viscosidade de uma formulação de proteína
EP3757126A1 (en) 2010-11-05 2020-12-30 Novartis AG Methods of treating psoriatic arthritis using il-17 antagonists
CN108715614A (zh) 2010-11-30 2018-10-30 中外制药株式会社 与多分子的抗原重复结合的抗原结合分子
CA2819679A1 (en) * 2010-12-02 2012-06-07 The Washington University Compositions and methods for treating amyloid plaque associated symptoms
MX2013010011A (es) 2011-03-01 2014-10-24 Amgen Inc Agentes de unión biespecífica.
SG193610A1 (en) 2011-03-25 2013-11-29 Amgen Inc Anti - sclerostin antibody crystals and formulations thereof
PL3404041T3 (pl) 2011-04-19 2020-12-14 Amgen Inc. Sposób leczenia osteoporozy
WO2012149246A1 (en) 2011-04-29 2012-11-01 Novartis Ag Methods of treating squamous cell carcinoma related applications
HUE039786T2 (hu) 2011-08-04 2019-02-28 Amgen Inc Csonthiány-defektusok kezelési módszere
UA115866C2 (uk) * 2011-09-22 2018-01-10 Екселіксіс, Інк. Спосіб лікування остеопорозу
SG11201403718YA (en) 2011-12-28 2014-07-30 Amgen Inc Method of treating alveolar bone loss through the use of anti-sclerostin antibodies
AU2013285488B2 (en) 2012-07-05 2018-03-22 Ucb Pharma S.A. Treatment for bone diseases
UY35148A (es) 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
WO2014118705A1 (en) 2013-01-31 2014-08-07 Novartis Ag Methods of treating chronic kidney disease-mineral and bone disorder using sclerostin antagonists
WO2014155278A2 (en) 2013-03-26 2014-10-02 Novartis Ag Methods of treating autoimmune diseases using il-17 antagonists
EP3200832B1 (en) 2014-09-30 2020-07-29 Washington University Tau kinetic measurements
MA41142A (fr) * 2014-12-12 2017-10-17 Amgen Inc Anticorps anti-sclérostine et utilisation de ceux-ci pour traiter des affections osseuses en tant qu'élements du protocole de traitement
AR103173A1 (es) 2014-12-22 2017-04-19 Novarits Ag Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
GB201604124D0 (en) 2016-03-10 2016-04-27 Ucb Biopharma Sprl Pharmaceutical formulation
BR112019012731A2 (pt) 2016-12-21 2019-11-26 Mereo Biopharma 3 Ltd uso de anticorpos antiesclerostina no tratamento de osteogênese imperfeita
US10961305B2 (en) 2016-12-21 2021-03-30 Mereo Biopharma 3 Limited Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta
EP3574010A4 (en) 2017-01-30 2020-12-16 Chugai Seiyaku Kabushiki Kaisha ANTI-SCLEROSTIN ANTIBODIES AND METHOD OF USE
MX2020010092A (es) 2018-03-30 2020-10-28 Amgen Inc Variantes de anticuerpo c-terminales.
GB201810746D0 (en) 2018-06-29 2018-08-15 Mereo Biopharma 3 Ltd Use of sclerostin antagonist
CN111658821A (zh) * 2020-06-03 2020-09-15 深圳市百吉因生物科技有限公司 负载小干扰rna的胶原基骨修复材料及制备方法及在制备治疗骨质疏松骨折材料中的应用
WO2024129988A1 (en) 2022-12-14 2024-06-20 Flagship Pioneering Innovations Vii, Llc Compositions and methods for delivery of therapeutic agents to bone

Family Cites Families (116)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4331647A (en) 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4411993A (en) 1981-04-29 1983-10-25 Steven Gillis Hybridoma antibody which inhibits interleukin 2 activity
US4427115A (en) 1981-10-19 1984-01-24 Laipply Thomas C One piece alcohol preparation device
USRE32011E (en) 1981-12-14 1985-10-22 Scripps Clinic And Research Foundation Ultrapurification of factor VIII using monoclonal antibodies
US4543439A (en) 1982-12-13 1985-09-24 Massachusetts Institute Of Technology Production and use of monoclonal antibodies to phosphotyrosine-containing proteins
US6054561A (en) 1984-02-08 2000-04-25 Chiron Corporation Antigen-binding sites of antibody molecules specific for cancer antigens
DE3417525C1 (de) 1984-05-11 1986-01-09 Matter + Siegmann Ag, Wohlen Vorrichtung zur quantitativen und qualitativen Erfassung von kohlenwasserstoffhaltigen Schwebeteilchen in Gasen
US4902614A (en) 1984-12-03 1990-02-20 Teijin Limited Monoclonal antibody to human protein C
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
MC2115A1 (fr) 1987-12-15 1991-07-05 Gene Shears Pty Ltd Ribozynes
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5571714A (en) 1988-12-22 1996-11-05 Celtrix Pharmaceuticals, Inc. Monoclonal antibodies which bind both transforming growth factors β1 and β2 and methods of use
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5549910A (en) 1989-03-31 1996-08-27 The Regents Of The University Of California Preparation of liposome and lipid complex compositions
US5244805A (en) 1989-05-17 1993-09-14 University Of Georgia Research Foundation, Inc. Baculovirus expression vectors
US5177197A (en) 1990-02-27 1993-01-05 Ludwig Institute For Cancer Research Isolated nucleotide sequence expressing human transforming growth factor-β1-binding protein
US5466468A (en) 1990-04-03 1995-11-14 Ciba-Geigy Corporation Parenterally administrable liposome formulation comprising synthetic lipids
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
JP3218637B2 (ja) 1990-07-26 2001-10-15 大正製薬株式会社 安定なリポソーム水懸濁液
EP0542810A1 (en) 1990-08-02 1993-05-26 B.R. Centre Limited Methods for the production of proteins with a desired function
JP2958076B2 (ja) 1990-08-27 1999-10-06 株式会社ビタミン研究所 遺伝子導入用多重膜リポソーム及び遺伝子捕捉多重膜リポソーム製剤並びにその製法
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5698426A (en) 1990-09-28 1997-12-16 Ixsys, Incorporated Surface expression libraries of heteromeric receptors
JPH04141095A (ja) 1990-10-02 1992-05-14 Chemo Sero Therapeut Res Inst 組換え抗ｈｉｖ改変抗体および改変抗体の調製方法
US5070108A (en) 1990-10-12 1991-12-03 Trustees Of The University Of Pennsylvania Methods of treating osteoporosis, increasing bone mineral content and preventing the occurrence of compression fractures in a mammal
WO1992006693A1 (en) 1990-10-22 1992-04-30 Fox Chase Cancer Center Dna construct for providing rna therapy
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5399363A (en) 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
WO1992019759A1 (en) 1991-04-25 1992-11-12 Chugai Seiyaku Kabushiki Kaisha Reconstituted human antibody against human interleukin 6 receptor
US5807683A (en) 1992-11-19 1998-09-15 Combichem, Inc. Combinatorial libraries and methods for their use
EP0708659A4 (en) 1993-06-07 2000-08-23 Genentech Inc HIV ENVELOPE POLYPEPTIDE
US5543158A (en) 1993-07-23 1996-08-06 Massachusetts Institute Of Technology Biodegradable injectable nanoparticles
US5453492A (en) 1993-07-28 1995-09-26 La Jolla Cancer Research Foundation 60 kDa transforming growth factor-β-binding protein and its use to detect or purify TGF-β
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
US5837458A (en) 1994-02-17 1998-11-17 Maxygen, Inc. Methods and compositions for cellular and metabolic engineering
DE69535641D1 (de) 1994-04-29 2007-12-27 Curis Inc Morphogene protein-spezifische zelloberflächenrezeptoren und ihre verwendungen
US5738996A (en) 1994-06-15 1998-04-14 Pence, Inc. Combinational library composition and method
DE4427221A1 (de) 1994-08-01 1996-02-08 Gsf Forschungszentrum Umwelt Retrovirus-induzierte Osteoklasten-Modulation für die Osteoporose-Therapie
US5846770A (en) 1994-11-22 1998-12-08 Genetics Institute, Inc. DNA molecules encoding human chordin
US6057421A (en) 1994-11-30 2000-05-02 Immpheron, Inc. Variable heavy and light chain regions of murine monoclonal antibody 1F7
US5723750A (en) 1995-01-12 1998-03-03 Vanderbilt University Transgenic plants expressing disassembly deficient viral coat proteins
US5795587A (en) 1995-01-23 1998-08-18 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
IE80468B1 (en) 1995-04-04 1998-07-29 Elan Corp Plc Controlled release biodegradable nanoparticles containing insulin
WO1996039486A1 (en) 1995-06-05 1996-12-12 Human Genome Sciences, Inc. Human ccn-like growth factor
US5738868A (en) 1995-07-18 1998-04-14 Lipogenics Ltd. Liposome compositions and kits therefor
ATE403001T1 (de) 1996-05-22 2008-08-15 Viventia Biotech Inc Antigenbindungsfragmente die spezifisch krebszellen nachweisen, nukleotide die für diese fragmente kodieren, und deren verwendung zur vorbeugung und zum nachweis von krebs
US6133426A (en) 1997-02-21 2000-10-17 Genentech, Inc. Humanized anti-IL-8 monoclonal antibodies
US5989909A (en) 1997-09-26 1999-11-23 Millennium Biotherapeutics, Inc. Huchordin and uses thereof
AU6959898A (en) 1997-04-11 1998-11-11 David J. Grainger Compounds and therapies for the prevention of vascular and non-vascular pathol ogies
US6278039B1 (en) 1997-05-28 2001-08-21 Axys Pharmaceuticals, Inc. C. elegans deletion mutants
JP3614866B2 (ja) 1997-06-12 2005-01-26 リサーチ コーポレイション テクノロジーズ，インコーポレイティド 人工抗体ポリペプチド
US6075007A (en) 1997-07-17 2000-06-13 Regeneron Pharmaceuticals, Inc. Modified noggin polypeptide and compositions
CA2297109A1 (en) 1997-08-01 1999-02-11 Genset 5' ests for secreted proteins expressed in muscle and other mesodermal tissues
US6815201B2 (en) 1997-09-08 2004-11-09 The Public Health Research Institute Of The City Of New York, Inc. HIV-1 gp120 V1/V2 domain epitopes capable of generating neutralizing antibodies
US6251588B1 (en) 1998-02-10 2001-06-26 Agilent Technologies, Inc. Method for evaluating oligonucleotide probe sequences
GB9818881D0 (en) * 1998-08-28 1998-10-21 Glaxo Group Ltd Compounds
US6544485B1 (en) 2001-01-29 2003-04-08 Sharper Image Corporation Electro-kinetic device with enhanced anti-microorganism capability
CN101469329B (zh) 1998-11-27 2012-10-24 达尔文发现有限公司 增加骨矿化的组合物和方法
US20040009535A1 (en) * 1998-11-27 2004-01-15 Celltech R&D, Inc. Compositions and methods for increasing bone mineralization
IL144578A0 (en) 1999-01-29 2002-05-23 Imclone Systems Inc Antibodies specific to kdr and uses thereof
US6110462A (en) 1999-03-03 2000-08-29 The Scripps Research Institute Enzymatic DNA molecules that contain modified nucleotides
ATE444971T1 (de) 1999-06-09 2009-10-15 Genentech Inc Zusammensetzungen und verfahren für die tumor- behandlung
US6197592B1 (en) * 1999-07-15 2001-03-06 Bio-Rad Laboratories, Inc. Clinical control materials for detection of bone resorptive markers
WO2001064885A1 (en) 2000-03-02 2001-09-07 Amgen, Inc. Chordin-like-2 molecules and uses thereof
EP1290169A2 (en) 2000-06-01 2003-03-12 Amgen, Inc. Cystine-knot polypeptides: cloaked-2 molecules and uses thereof
US20040132021A1 (en) 2000-06-19 2004-07-08 Wendy Balemans Osteolevin gene polymorphisms
CA2632702A1 (en) 2000-09-01 2002-03-28 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
DE60139944D1 (de) 2000-10-12 2009-10-29 Genentech Inc Niederviskose konzentrierte proteinformulierungen
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
CA2374027A1 (en) 2001-03-13 2002-09-13 The Minister Of National Defence Cloning, expression, sequencing, and functional enhancement of monoclonal scfv antibody against venezuelan equine encephalitis virus(vee)
DE10145772A1 (de) 2001-09-17 2003-04-10 Bayer Cropscience Ag DELTA·1·-Pyrroline
US7261892B2 (en) 2001-11-27 2007-08-28 Celltech R&D Limited Methods for diagnosis and treatment of epithelial-derived cancers
US7030403B2 (en) 2001-12-06 2006-04-18 Biocontrol Systems, Inc. Sample collection and bioluminescent sample testing system
US20030186915A1 (en) 2002-02-11 2003-10-02 Yang Pan Regulatory polynucleotides and uses thereof
EP2277522B1 (en) 2002-03-01 2012-11-21 UCB Manufacturing, Inc. Methods for increasing or decreasing bone density and identifying molecules
US7799523B2 (en) 2002-04-03 2010-09-21 Celltech R & D, Inc. Association of polymorphisms in the SOST gene region with bone mineral density
FR2838379B1 (fr) 2002-04-12 2005-06-24 Valeo Climatisation Dispositif de purification de l'air de l'habitacle d'un vehicule automobile
US20040023356A1 (en) 2002-06-14 2004-02-05 Robb Krumlauf Wise/Sost nucleic acid sequences and amino acid sequences
US7893218B2 (en) 2003-06-16 2011-02-22 Stowers Institute For Medical Research Antibodies that specifically bind SOST peptides
CA2504493C (en) 2002-11-01 2015-12-29 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method of preventing infections from bioterrorism agents with immunostimulatory cpg oligonucleotides
JP2006507841A (ja) 2002-11-14 2006-03-09 ダーマコン， インコーポレイテッド 機能的ｓｉＲＮＡおよび超機能的ｓｉＲＮＡ
DE10255152A1 (de) 2002-11-26 2004-06-03 Von Langen Ursula Lang Schadstoffsauger
US7642238B2 (en) 2002-12-05 2010-01-05 Shaughnessy John D Molecular determinants of myeloma bone disease and uses thereof
US20040141875A1 (en) 2003-01-15 2004-07-22 Rajiv Doshi System and method for treating microorganisms within motor vehicle heating, ventilation, and air conditioning units
EP1608399B1 (en) 2003-03-14 2012-01-11 Ucb Manufacturing, Inc. Complex of sclerostin and noggin or chordin, and agents that modulate the formation of said complex
WO2004090105A2 (en) 2003-04-02 2004-10-21 Dharmacon, Inc. Modified polynucleotides for use in rna interference
US20050158303A1 (en) 2003-04-04 2005-07-21 Genentech, Inc. Methods of treating IgE-mediated disorders comprising the administration of high concentration anti-IgE antibody formulations
CU23403A1 (es) 2003-04-23 2009-08-04 Centro Inmunologia Molecular Anticuerpos recombinantes y fragmentos que reconocen el gangliósido n-glicolil gm3 y su uso para diagnóstico y tratamiento de tumores
EA015166B1 (ru) 2003-06-16 2011-06-30 Ю-Си-Би Мэньюфэкчуринг, Инк. Иммуногенные пептиды склеростина (sost), индуцирующие образование специфических антител
US8461155B2 (en) 2003-09-22 2013-06-11 University Of Connecticut Sclerostin and the inhibition of WNT signaling and bone formation
EP2123759B1 (en) 2004-02-06 2014-01-15 Thermo Fisher Scientific Biosciences Inc. Stabilized RNAS as transfection controls and silencing reagents
KR101147147B1 (ko) 2004-04-01 2012-05-25 머크 샤프 앤드 돔 코포레이션 Ｒｎａ 간섭의 오프 타겟 효과 감소를 위한 변형된폴리뉴클레오타이드
US20050267233A1 (en) 2004-05-25 2005-12-01 Joshi Ashok V Anti-microbial handle system
US7709611B2 (en) 2004-08-04 2010-05-04 Amgen Inc. Antibodies to Dkk-1
US8003108B2 (en) 2005-05-03 2011-08-23 Amgen Inc. Sclerostin epitopes
US7592429B2 (en) 2005-05-03 2009-09-22 Ucb Sa Sclerostin-binding antibody
US8541177B2 (en) * 2006-01-13 2013-09-24 A Chan Holding B.V. Treatment and diagnosis of abnormal bone density with an inhibitor of the glypican-sclerostin interaction
US20100015665A1 (en) 2006-11-10 2010-01-21 Ucb Pharma S.A. Antibodies and diagnostics
US20100036091A1 (en) 2006-11-10 2010-02-11 Amgen Inc. Antibody-based diagnostics and therapeutics
US20080120672A1 (en) 2006-11-21 2008-05-22 Francesco Caggioni Methods and Apparatus for Weighted Multicasting of Data Streams
EP3345607B1 (en) 2006-12-29 2022-10-26 Ossifi-Mab LLC Methods of altering bone growth by administration of sost or wise antagonist or agonist
BRPI0807205A2 (pt) 2007-02-02 2014-07-22 Novartis Ag Moduladores de ligantes esclerostina para tratamento de distúrbios relacionados ao osso
BRPI0809026A2 (pt) * 2007-03-20 2014-09-23 Lilly Co Eli Anticorpos antiesclerotina
JOP20080381B1 (ar) 2007-08-23 2023-03-28 Amgen Inc بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9)
CL2008002775A1 (es) 2007-09-17 2008-11-07 Amgen Inc Uso de un agente de unión a esclerostina para inhibir la resorción ósea.
AR068767A1 (es) 2007-10-12 2009-12-02 Novartis Ag Anticuerpos contra esclerostina, composiciones y metodos de uso de estos anticuerpos para tratar un trastorno patologico mediado por esclerostina
EA201000718A1 (ru) 2007-11-02 2011-06-30 Новартис Аг Молекулы и способы, предназначенные для модуляции родственного рецептору липопротеидов низкой плотности белка 6 (lrp6)
US20110044978A1 (en) 2007-12-14 2011-02-24 Amgen Inc. Method for treating bone fracture
NZ589434A (en) 2008-06-03 2012-11-30 Abbott Lab Dual variable domain immunoglobulins and uses thereof
WO2010100179A2 (en) 2009-03-05 2010-09-10 Novartis Ag Self-forming gel system for sustained drug delivery
AR075715A1 (es) 2009-03-05 2011-04-20 Novartis Ag Formulacion de anticuerpo liofilizado
WO2010115932A1 (en) 2009-04-08 2010-10-14 Novartis Ag Combination for the treatment of bone loss
WO2010130830A2 (en) 2009-05-15 2010-11-18 Ablynx N.V. Amino acid sequences directed against sclerostin and polypeptides comprising the same for the treatment of bone diseases and disorders
WO2012028683A1 (en) 2010-09-02 2012-03-08 Novartis Ag Antibody gel system for sustained drug delivery
EP2632951B1 (en) 2010-10-27 2017-08-02 Amgen Inc. Dkk1 antibodies and methods of use

Also Published As

Publication number Publication date
AU2008302313B2 (en) 2013-10-31
US20110268730A1 (en) 2011-11-03
PL3085386T3 (pl) 2020-11-30
EP4335510A2 (en) 2024-03-13
EP2195026B1 (en) 2013-12-25
TW200930403A (en) 2009-07-16
CY1117908T1 (el) 2017-05-17
AU2008302313C1 (en) 2014-04-03
SI2556841T1 (sl) 2016-10-28
CY1114961T1 (el) 2016-12-14
US8329176B2 (en) 2012-12-11
JP5764704B2 (ja) 2015-08-19
PT2195026E (pt) 2014-03-31
WO2009039175A3 (en) 2009-05-07
JP2010539190A (ja) 2010-12-16
DK2556841T3 (da) 2016-08-15
US10273293B2 (en) 2019-04-30
US20210340236A1 (en) 2021-11-04
JP2015038076A (ja) 2015-02-26
HRP20160872T1 (hr) 2016-09-23
LT3085386T (lt) 2020-11-25
ES2815677T3 (es) 2021-03-30
JP5643094B2 (ja) 2014-12-17
MX2010002971A (es) 2010-08-10
DK2195026T3 (da) 2014-03-03
SI2195026T1 (sl) 2014-04-30
LT3725329T (lt) 2024-03-25
PT3725329T (pt) 2024-03-14
EP2195026A2 (en) 2010-06-16
TWI526222B (zh) 2016-03-21
PT3085386T (pt) 2020-09-15
US20090074763A1 (en) 2009-03-19
HUE050653T2 (hu) 2020-12-28
HUE030168T2 (en) 2017-05-29
US8440193B2 (en) 2013-05-14
CA2699905C (en) 2023-09-05
LT2556841T (lt) 2016-09-12
US8017120B2 (en) 2011-09-13
DK3725329T3 (da) 2024-03-18
EP3085386B1 (en) 2020-06-24
EP3725329B1 (en) 2024-01-31
AR109995A2 (es) 2019-02-13
HRP20201438T1 (hr) 2020-11-27
PL2195026T3 (pl) 2014-05-30
PL2556841T3 (pl) 2016-11-30
CY1123463T1 (el) 2022-03-24
PL3725329T3 (pl) 2024-06-10
US9089553B2 (en) 2015-07-28
US20130287764A1 (en) 2013-10-31
CA2699905A1 (en) 2009-03-26
PT2556841T (pt) 2016-07-25
AU2008302313A1 (en) 2009-03-26
CL2008002775A1 (es) 2008-11-07
ES2581754T3 (es) 2016-09-07
AR068471A1 (es) 2009-11-18
EP3085386A1 (en) 2016-10-26
SI3725329T1 (sl) 2024-04-30
HK1182017A1 (zh) 2013-11-22
EP2556841B1 (en) 2016-05-11
FI3725329T3 (fi) 2024-03-18
HRP20140153T1 (hr) 2014-04-25
US20190100580A1 (en) 2019-04-04
WO2009039175A2 (en) 2009-03-26
ES2445792T3 (es) 2014-03-05
EP4335510A3 (en) 2024-06-26
US20110262433A1 (en) 2011-10-27
US20150274817A1 (en) 2015-10-01
US11091537B2 (en) 2021-08-17
TW201622747A (zh) 2016-07-01
EP2556841A1 (en) 2013-02-13
TWI612972B (zh) 2018-02-01
EP3725329A1 (en) 2020-10-21
SI3085386T1 (sl) 2020-11-30
EP2556841B9 (en) 2017-09-06
CA3170836A1 (en) 2009-03-26

Similar Documents

Publication Publication Date Title
DK3085386T3 (da) Fremgangsmåde til hæmning af knogleresorption
DK2068927T3 (da) Fremgangsmåder til reducering af eosinofilniveauer
DK2044002T3 (da) Fremgangsmåde til fremstilling af 3-substituerede 2-amino-5-halobenzamider
DK2035166T3 (da) Fremgangsmåde til fremstilling af beholdere
BRPI0814359A2 (pt) Método
DK2436360T3 (da) System til udførelse af iskæmisk fjernprækonditionering
DK3178792T3 (da) Fremgangsmåde til aflejringshæmning
DK1844662T3 (da) Metode til belægning af objekter
BRPI0812176A2 (pt) Método de cimentar poço
DK2310034T3 (da) Peptider til behandling af beta-amyloidose
DK1852430T3 (da) Fremgangsmåde til fremstilling af proanthocyanidinoligomer
DK2215031T3 (da) Fremgangsmåde til bearbejdning af pozzolaner
DK2126801T3 (da) Fremgangsmåde til udvælgelse af information
DK2061746T3 (da) Fremgangsmåde til fremstilling af diestere
DK1990811T3 (da) Fremgangsmåde til beskyttelse af permanent magnet
BRPI0716528A2 (pt) mÉtodo de estabilizaÇço
DK2213654T3 (da) Fremgangsmåde til fremstilling af 2-amino-5-brombenzamid derivater
DK2166875T3 (da) Fremgangsmåde til fjernelse af lugt fra vineddike
DK2160225T3 (da) Fremgangsmåde til fremstilling af krystaller
DK2019118T3 (da) Fremgangsmåde til syntetisering af thymosiner
DK2201020T3 (da) Fremgangsmåde til fremstilling af 2' -deoxy-5-azacytidin (decitabin)
FI20065363A0 (fi) Erotusmenetelmä
DK2342346T3 (da) Thermotoga til behandling af biomasse
DK2262739T3 (da) Fremgangsmåde til neutralisering af mikroorganismer
DK2441462T3 (da) Fremgangsmåde til behandling af type I-diabetes